Caplin Partners With Xellia For Five Injectables
Company Is Ready To Launch One Approved Generic
With a pipeline of over 35 ANDAs, India's Caplin Steriles plans to launch five generic injectables through a strategic partnership with Xellia Pharma in the US market. Out of the five ANDAs, one has been approved and is ready for launch.
You may also be interested in...
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.
The US FDA’s ‘Purple Book’ which was created “to improve transparency and functionality for stakeholders by providing a complete view of biological product options” has been updated after being recently transitioned into an online database.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.